Mitochondria and oxidative stress in epilepsy: advances in antioxidant therapy
Frontiers in Pharmacology · 19.03.2025 · 15
DOI: 10.3389/fphar.2024.1505867 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 19.03.2025. Verfasst von Delphine Ji und 5 weiteren Autor:innen. Beteiligte Einrichtung: Krembil Research Institute, Toronto, ON, Canada. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 143 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Epilepsy, affecting approximately 50 million individuals worldwide, is a neurological disorder characterized by recurrent seizures. Mitochondrial dysfunction and oxidative stress are critical factors in its pathophysiology, leading to neuronal hyperexcitability and cell death. Because of the multiple mitochondrial pathways that can be involved in epilepsy and mitochondrial dysfunction, it is optimal to treat epilepsy with multiple antioxidants in combination. Recent advancements highlight the potential of antioxidant therapy as a novel treatment strategy. This approach involves tailoring antioxidant interventions—such as melatonin, idebenone, and plant-derived compounds—based on individual mitochondrial health, including mitochondrial DNA mutations and haplogroups that influence oxidative stress susceptibility and treatment response. By combining antioxidants that target multiple pathways, reducing oxidative stress, modulating neurotransmitter systems, and attenuating neuroinflammation, synergistic effects can be achieved, enhancing therapeutic efficacy beyond that of a single antioxidant on its own. Future directions include conducting clinical trials to evaluate these combination therapies, and to translate preclinical successes into effective clinical interventions. Targeting oxidative stress and mitochondrial dysfunction through combination antioxidant therapy represents a promising adjunctive strategy to modify disease progression and improve outcomes for individuals living with epilepsy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Krembil Research Institute, Toronto, ON, Canada.
- Departments of Medicine and Physiology, University of Toronto, Toronto, ON, Canada.
- Department of Pediatrics, McMaster Children's Hospital, Hamilton, ON, Canada.
- Biomedical Engineering, University of Toronto, Toronto, ON, Canada.
Zitieren
APA
Ji, D., Mylvaganam, S., Ravi Chander, P., Tarnopolsky, M., Murphy, K., & Carlen, P. (2025). Mitochondria and oxidative stress in epilepsy: advances in antioxidant therapy. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1505867
Vancouver
Ji D, Mylvaganam S, Ravi Chander P, Tarnopolsky M, Murphy K, Carlen P. Mitochondria and oxidative stress in epilepsy: advances in antioxidant therapy. Frontiers in Pharmacology. 2025;15. doi:10.3389/fphar.2024.1505867
BibTeX
@article{Ji2025,
author = {Ji, Delphine and Mylvaganam, Shanthini and Ravi Chander, Prathyusha and Tarnopolsky, Mark and Murphy, Keiran and Carlen, Peter},
title = {Mitochondria and oxidative stress in epilepsy: advances in antioxidant therapy},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {15},
doi = {10.3389/fphar.2024.1505867}
}
EUVIMED